Introduction: There are limited data on factors associated with retention in Option B+. We sought to explore the characteristics of women retained in Option B+ in Malawi, with a focus on the role of HIV disclosure, awareness of partner HIV status, and knowledge around the importance of Option B+ for maternal–child health.Methods: We performed a case-control study of HIV-infected women in Malawi initiated on antiretroviral therapy (ART) under Option B+. Cases were enrolled if they met criteria for default from Option B+ (out of ART for >60 days), and controls were enrolled in approximately 3:1 ratio if they were retained in care for at least 12 months. We surveyed socio-demographic characteristics, HIV disclosure and awareness of partner HIV...
INTRODUCTION: Data from the Option B+ prevention of mother-to-child transmission (PMTCT) program in ...
Introduction: The implementation of lifelong antiretroviral treatment (ART) for all pregnant women (...
Abstract Background Lifelong antiretroviral therapy for HIV infected pregnant and lactating women (O...
IntroductionThere are limited data on factors associated with retention in Option B+. We sought to e...
IntroductionThere are limited data on factors associated with retention in Option B+. We sought to e...
Background: Malawi launched Option B+ in July 2011, a program for all pregnant or breastfeeding HIV-...
Background Studies of Malawi's option B+ programme for HIV-positive pregnant and breastfeeding wo...
Background and Objective: Retaining women in Option B+ services is crucial for eliminating new pedia...
Background: Post-partum loss to follow-up and lack of early HIV infant diagnosis (EID) can significa...
Background: Post-partum loss to follow-up and lack of early HIV infant diagnosis (EID) can significa...
Background: Post-partum loss to follow-up and lack of early HIV infant diagnosis (EID) can significa...
Although several studies have documented challenges related to inadequate adherence to antiretrovira...
Background: Post-partum loss to follow-up and lack of early HIV infant diagnosis (EID) can significa...
The implementation of 'Option B+' has increased uptake and access to antiretroviral (ART) care. Howe...
Introduction: Malawi introduced a new strategy to improve the effectiveness of prevention of mother-...
INTRODUCTION: Data from the Option B+ prevention of mother-to-child transmission (PMTCT) program in ...
Introduction: The implementation of lifelong antiretroviral treatment (ART) for all pregnant women (...
Abstract Background Lifelong antiretroviral therapy for HIV infected pregnant and lactating women (O...
IntroductionThere are limited data on factors associated with retention in Option B+. We sought to e...
IntroductionThere are limited data on factors associated with retention in Option B+. We sought to e...
Background: Malawi launched Option B+ in July 2011, a program for all pregnant or breastfeeding HIV-...
Background Studies of Malawi's option B+ programme for HIV-positive pregnant and breastfeeding wo...
Background and Objective: Retaining women in Option B+ services is crucial for eliminating new pedia...
Background: Post-partum loss to follow-up and lack of early HIV infant diagnosis (EID) can significa...
Background: Post-partum loss to follow-up and lack of early HIV infant diagnosis (EID) can significa...
Background: Post-partum loss to follow-up and lack of early HIV infant diagnosis (EID) can significa...
Although several studies have documented challenges related to inadequate adherence to antiretrovira...
Background: Post-partum loss to follow-up and lack of early HIV infant diagnosis (EID) can significa...
The implementation of 'Option B+' has increased uptake and access to antiretroviral (ART) care. Howe...
Introduction: Malawi introduced a new strategy to improve the effectiveness of prevention of mother-...
INTRODUCTION: Data from the Option B+ prevention of mother-to-child transmission (PMTCT) program in ...
Introduction: The implementation of lifelong antiretroviral treatment (ART) for all pregnant women (...
Abstract Background Lifelong antiretroviral therapy for HIV infected pregnant and lactating women (O...